Literature DB >> 14989741

Expression of MAGE-A3 in intrahepatic cholangiocarcinoma and its precursor lesions.

Koichi Tsuneyama1, Motoko Sasaki, Tomonori Shimonishi, Yasuni Nakanuma.   

Abstract

MAGE-A3 antigen is known to be neo-expressed in a large proportion of tumors but not detectable in normal tissues, and could be a target antigen recognized by autologous cytotoxic T lymphocytes. In the present study, the expression of MAGE-A3 at protein and mRNA levels was examined in intrahepatic cholangiocarcinoma (ICC) and its precursor lesions. Carcinomatous and dysplastic biliary cells expressed MAGE-A3 in their cytoplasm diffusely, although there was no MAGE-A3 expression in normal and hyperplastic biliary cells. MAGE-A3 was expressed in one of 10 cases (10%) of low-grade dysplasia, four of 13 (31%) cases of high-grade dysplasia/in situ carcinoma, and 32 of 68 invasive ICC cases (47%), respectively. The MAGE-A3 mRNA expression pattern was similar to that of MAGE-A3 protein. The incidence and intensity of MAGE-A3 expression increased along the progression of biliary neoplasia (P < 0.05). There was no correlation between MAGE-3 expression and histological differentiation or anatomical locations of invasive ICC. MAGE-A3 is a promising target molecule for the specific immunotherapy of ICC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14989741     DOI: 10.1111/j.1440-1827.2003.01605.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  7 in total

1.  Targeting the MAGE A3 antigen in pancreatic cancer.

Authors:  Alexandria P Cogdill; Dennie T Frederick; Zachary A Cooper; Haven R Garber; Cristina R Ferrone; Amy Fiedler; Laura Rosenberg; Sarah P Thayer; Andrew L Warshaw; Jennifer A Wargo
Journal:  Surgery       Date:  2012-07-06       Impact factor: 3.982

2.  CpG island hypermethylation and repetitive DNA hypomethylation in premalignant lesion of extrahepatic cholangiocarcinoma.

Authors:  Baek-hui Kim; Nam-Yun Cho; So Hyun Shin; Hyeong-Ju Kwon; Ja June Jang; Gyeong Hoon Kang
Journal:  Virchows Arch       Date:  2009-09-10       Impact factor: 4.064

3.  The FDA guidance on therapeutic cancer vaccines: the need for revision to include preventive cancer vaccines or for a new guidance dedicated to them.

Authors:  Olivera J Finn; Samir N Khleif; Ronald B Herberman
Journal:  Cancer Prev Res (Phila)       Date:  2015-09-09

4.  Cancer-testis antigens are predominantly expressed in uterine leiomyosarcoma compared with non-uterine leiomyosarcoma.

Authors:  Kunio Iura; Kenichi Kohashi; Nobuko Yasutake; Takeaki Ishii; Akira Maekawa; Hirofumi Bekki; Hiroshi Otsuka; Yuichi Yamada; Hidetaka Yamamoto; Yoshihiro Ohishi; Yoshihiro Matsumoto; Yukihide Iwamoto; Yoshinao Oda
Journal:  Oncol Lett       Date:  2017-10-26       Impact factor: 2.967

5.  Use of carcinogen-induced premalignant oral lesions in a dendritic cell-based vaccine to stimulate immune reactivity against both premalignant oral lesions and oral cancer.

Authors:  M Rita I Young
Journal:  J Immunother       Date:  2008 Feb-Mar       Impact factor: 4.456

6.  Expression and prognostic significance of cancer-testis antigens (CTA) in intrahepatic cholagiocarcinoma.

Authors:  Jin-Xue Zhou; Yin Li; Sun-Xiao Chen; An-Mei Deng
Journal:  J Exp Clin Cancer Res       Date:  2011-01-06

Review 7.  Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers.

Authors:  Inga Hochnadel; Uta Kossatz-Boehlert; Nils Jedicke; Henrike Lenzen; Michael P Manns; Tetyana Yevsa
Journal:  Hum Vaccin Immunother       Date:  2017-11-07       Impact factor: 3.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.